Regression of retinal capillary hemangioblastoma with systemic belzutifan in von Hippel–Lindau disease: a case report - Takeaways - MDSpire

Regression of retinal capillary hemangioblastoma with systemic belzutifan in von Hippel–Lindau disease: a case report

  • By

  • Angelica Aja Dangca Alcoreza

  • Cheryn Song

  • Junyeop Lee

  • July 9, 2026

  • 0 min

Share

  • 1

    A 49-year-old female with von Hippel–Lindau disease experienced regression of retinal capillary hemangioblastoma after systemic belzutifan treatment.

  • 2

    Belzutifan, a HIF-2α inhibitor, was initiated due to new retinal lesions and renal mass growth in the patient.

  • 3

    After four months of belzutifan therapy, the patient showed reduced size, perfusion, and vascularity of retinal lesions.

  • 4

    The patient's visual acuity improved to 20/16, and local ablative therapies were deferred due to the positive response.

  • 5

    Belzutifan may serve as an effective treatment for retinal capillary hemangioblastomas in patients with VHL disease.

Original Source(s)

Regression of retinal capillary hemangioblastoma with systemic belzutifan in von Hippel–Lindau disease: a case report

  • by Angelica Aja Dangca Alcoreza, Cheryn Song, Junyeop Lee

  • July 9, 2026

Related Content

Smartphones Spot Ocular Malignancies

Could a smartphone-based AI system bring ocular oncology screening directly into the patient’s home?

  • July 2, 2026

  • 3 min
Changes in retinal venous diameter in proliferative diabetic retinopathy patients with diabetic macular edema following faricimab treatment: an observational study

Application effect and teaching evaluation of case-based learning combined with ChatGPT in ophthalmology clinical teaching